Oral small-molecule GLP-1RA safiglipron versus dapagliflozin in type 2 diabetes: a randomized, double-blind, active-comparator-controlled phase 3 trial.

Safiglipron at all tested doses is non-inferior to dapagliflozin in reducing HbA1c in adults with type 2 diabetes over 32 weeks.

• Why it matters: Effective oral treatments for type 2 diabetes are needed that do not require fasting or dietary restrictions, addressing limitations of existing therapies.
• What they did: A phase 3 trial randomized 810 adults to receive safiglipron (30, 60, or 90 mg) or dapagliflozin 10 mg for 32 weeks, assessing changes in HbA1c and safety outcomes.
• The result: All safiglipron doses achieved non-inferiority, with the 90 mg dose also showing superiority in HbA1c reduction, and it improved glycemic control, weight, and treatment satisfaction despite mild gastrointestinal side effects.